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Exosome-mediated shuttling of microRNA-29
regulates HIV Tat and morphine-mediated Neuronal
dysfunction
G Hu1,3, H Yao1,3, AD Chaudhuri1, M Duan1, SV Yelamanchili1, H Wen1, PD Cheney2, HS Fox1 and S Buch*,1
Neuronal damage is a hallmark feature of HIV-associated neurological disorders (HANDs). Opiate drug abuse accelerates the
incidence and progression of HAND; however, the mechanisms underlying the potentiation of neuropathogenesis by these
drugs remain elusive. Opiates such as morphine have been shown to enhance HIV transactivation protein Tat-mediated toxicity
in both human neurons and neuroblastoma cells. In the present study, we demonstrate reduced expression of the tropic factor
platelet-derived growth factor (PDGF)-B with a concomitant increase in miR-29b in the basal ganglia region of the brains of
morphine-dependent simian immunodeficiency virus (SIV)-infected macaques compared with the SIV-infected controls. In vitro
relevance of these findings was corroborated in cultures of astrocytes exposed to morphine and HIV Tat that led to increased
release of miR-29b in exosomes. Subsequent treatment of neuronal SH-SY5Y cell line with exosomes from treated astrocytes
resulted in decreased expression of PDGF-B, with a concomitant decrease in viability of neurons. Furthermore, it was shown that
PDGF-B was a target for miR-29b as evidenced by the fact that binding of miR-29 to the 30-untranslated region of PDGF-B mRNA
resulted in its translational repression in SH-SY5Y cells. Understanding the regulation of PDGF-B expression may provide
insights into the development of potential therapeutic targets for neuronal loss in HIV-1-infected opiate abusers.
Cell Death and Disease (2012) 3, e381; doi:10.1038/cddis.2012.114; published online 30 August 2012
Subject Category: Neuroscience
Though the majority of HIV-infected individuals acquired
infection through sexual contact, a growing number acquire
the virus via intravenous drug use. The most commonly
injected illicit drug is heroin. Combined HIV-1 infection and
opiate dependence is becoming an emerging problem in the
post-combination anti-retroviral treatment era, as infected
individuals continue to live longer. It is estimated that drug
abuse may be the leading cause of HIV transmission in the
United States. The interplay of these two thus raises concerns
regarding their effects on disease severity and rate of
progression.1 Opiates, such as morphine and heroin, are
drugs of choice in a large number of injecting drugs users.
There exists a strong connection between opiate usage and
HIV-1 neuropathogenesis, and opiate use has been reported
to correlate with increased severity of central nervous system
(CNS) disease through a number of potential mechanisms.2
Morphine is an opioid analgesic that is used extensively in the
clinical setting. Heroin is a semi-synthetic ester of morphine
and exerts its effect following its conversion to morphine in the
brain.3 Opiate abuse has the potential to destabilize neuronal
functions, thereby leading to acceleration of neurological
complications. Studies on effects of drugs of abuse on HIV
infection have been problematic to conduct, primarily because
of high variability in drug-usage patterns, length of use and
multidrug use, as well as differences in nutritional status and
access to medical care.4 Animal models therefore provide a
valuable approach to study the effects of opiates on lentivirus
pathogenesis in a more controlled environment. Several
studies have utilized the simian immunodeficiency virus
(SIV)/AIDS macaque model to better understand the influ-
ence of opiate dependency on HIV progression to AIDS. The
questions on morphine effects regarding worsening or
prevention of disease are relevant in this model system.
Previous study reported that morphine dependence in SIV
(R71/17E)-infected rhesus macaques, a SIVmac239 deriva-
tive, resulted in potentiation of virus replication and con-
comitant neuronal apoptosis in the CNS compared with
macaques infected with the virus alone.5,6
Neuronal homeostasis is controlled by neurotropic factors,
such as brain-derived neurotrophic factor and platelet-derived
growth factor (PDGF).7 Interestingly, HIV proteins such as Tat
and gp120 can downregulate expression of tropic factors such
as PDGF, leading to increased neuronal apoptosis. PDGF
belongs to a family of five dimeric ligands assembled from four
gene products (PDGF-A–D) that act via two classical receptor
tyrosine kinases, PDGF-aR and PDGF-bR. It must be noted
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that nomenclature of PDGF-B refers to RNA expression,
whereas that of PDGF-BB refers to the protein expression of
PDGF-B chain genes. Members of the PDGF family have
multiple functions during embryogenesis and in a variety of
pathological situations in the adult.8 Among these members,
PDGF has been demonstrated to protect primary hippocam-
pal neurons against glutamate-induced neuronal damage.9
PDGF has been shown to promote long-term survival in
cultured brain neurons and cultured mesencephalic dopami-
nergic neurons.10 In addition, PDGF has also been shown to
exert protection against the HIV envelope protein-mediated
toxicity in neurons.11 In our recent study on SIV-infected
morphine-dependent macaques, we observed high viral load
in cerebrospinal fluid (CSF) that was accompanied with
increased neuronal apoptosis.5 We thus hypothesized that
morphine potentiated SIV-mediated neuronal apoptosis likely
via downregulation of the tropic factor PDGF-B chain in
neurons, and this in turn, could be regulated by microRNA(s)
specific for PDGF-B.
MicroRNAs are small RNA regulators that have essential
roles in various biological processes.12 MiRNA-mediated
regulation is gaining popularity in neuronal development,
neuronal plasticity and neuronal differentiation.12 Elegant
studies have revealed that miRNAs have pivotal roles in
neuronal development as well as in the control of neuronal
functional elements. Various miRNAs are being recognized
with links to HIVE/SIVE,13 such as Parkinson’s, Alzheimer’s
and Huntington’s diseases.14
In this study, we demonstrate that miR-29b is increased in
the basal ganglia in brains of SIV-infected rhesus macaques
that were morphine-dependent. We further demonstrate that
this effect was indirect as exosomes released from astrocytes
treated withmorphine and HIV Tat can shuttlemiR-29b, which
can be taken up by neurons leading to neuronal death.
Moreover, conditioned media (CM) from astroctyes treated
with both Tat and morphine decreased PDGF-B expression
and enhanced neuronal apoptosis in neurons.
Results
MiRNA profiling in the basal ganglia of SIV-infected
macaques with and without morphine dependence. As
miRNAs have pivotal roles in neuronal function, we first
examined the expression profile of miRNAs in the basal
ganglia of uninfected (n¼5) and SIV-infected macaques with
(n¼5) and without (n¼ 5) morphine dependence. For details
of morphine dose and treatment, and the virus used, please
refer to the study by Bokhari et al.5 Figure 1a is a heat map of
the miRNA profile observed in the basal ganglia of SIV-
infected macaques with and without morphine dependence
compared with the uninfected controls. Supplementary
Table 1 demonstrates some of the other up- and down-
regulated miRNAs in the basal ganglia of SIV-infected
macaques with and without morphine dependence.
Of these altered miRNA profiles, miR-29b was of particular
interest, as it was upregulated 4.3-fold in the brains of SIV-
infected macaques that are morphine-dependent, and more
so, as one of its predicted target genes, PDGF-B chain, has
been demonstrated to regulate neuronal survival.15 To
validate upregulation of miR-29b, we sought to evaluate its
expression in the basal ganglia isolated from the various
macaque groups using the mature miRNA-specific quantita-
tive PCR. As shown in Figure 1b, and in keeping with the
miRNA array data, there was increased expression of miR-
29b in the basal ganglia of SIV-infected macaques that were
morphine-dependent comparedwith either the SIV-infected or
-uninfected control groups. These findings were further
validated by in situ hybridization, demonstrating increased
expression of miR-29b both in the neurons and astrocytes in
the brains of SIV-infected macaques with morphine depen-
dence (Figure 1c) compared with SIV-infected macaques.
Upregulation of miR-29b was not specific to basal ganglia, as
other brain regions such as cortex also demonstrated
increased expression of miR-29b in both SIV and morphine-
dependent macaques (Supplementary Figure 1).
Downregulation of PDGF-B in basal ganglia of SIV-
infected macaques with opiate abuse. Our previous
studies have demonstrated decreased expression of
PDGF-B in neurons exposed to HIV proteins as well as in
the brains of SIV-infected macaques.15 Intriguingly, PDGF-B
is a neurotropic factor whose downregulation has been
shown to correlate with neuronal damage.15 To understand
the impact of opiate dependence on neuronal damage and,
in turn, expression of PDGF-B, we examined by western blot
and real-time PCR the levels of PDGF-B in the basal ganglia
of untreated or SIV-infected macaques with or without drug
dependence. As shown in Figure 2a, basal ganglia from SIV-
infected, morphine-dependent macaques demonstrated sig-
nificant decrease in the expression of PDGF-B compared
with the untreated or SIV-infected groups. However, contrary
to the decrease in protein levels, PDGF-B mRNA levels in the
basal ganglia of SIV-infected, morphine-dependent maca-
ques were upregulated, thereby suggesting posttranscrip-
tional regulation of PDGF-B protein (Figure 2b).
CM from HIV-1 Tat and morphine-treated astrocytes
downregulates PDGF-B expression in neurons. Having
determined the effect of SIV-infection and morphine-depen-
dence on downregulation of PDGF-B, the next step was to
confirm these findings in purified cultures of SH-SY5Y
neurons. We therefore sought to determine whether treat-
ment of either a neuron cell line or primary rat neurons to
exogenous morphine and/or HIV protein Tat (neurotoxin used
here as a substitute for SIV/HIV infection in the CNS, as
neurons are not directly infectable by the virus, but are
affected by viral proteins) could downregulate expression of
PDGF-B. Interestingly, treatment of SH-SY5Y cells or rat
primary neurons with morphine (107M; concentration based
on previous findings16) and/or Tat protein (200ng/ml) failed to
decrease PDGF-B expression (data not shown). These
finding are consistent with previous reports that neurons are
more sensitive to Tat and/or morphine in the presence of
astrocytes,17 based on the fact that in the CNS microenviron-
ment, neuronal homeostasis depends on continuous com-
munication between the astrocytes and neurons.18
On the basis of these reports and the fact that astrocytes
have pivotal roles in neuron survival via transport of nutrients
and other substances to the neurons,19 we sought to examine
the effect of morphine and/or Tat on the ability of astrocytes to
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provide tropic support to neurons. The next series of
experiments were thus done using CM collected from either
rat primary astrocytes or human astrocytoma A172 cells
treated with morphine and/or Tat for 24 h. The nomenclature
used for various CM were as follows – untreated, control
astrocyte CM (CACM); morphine-treated astrocyte CM; Tat-
treated astrocyte CM (TACM); and morphine plus TACM
(MTACM). As shown in Figure 3, exposure of either the rat
primary neurons (Figure 3a), the SH-SY5Y cell line (Figure 3c)
or differentiated (retinioic acid-treated) SH-SY5Y cells
(Figure 3e) to MTACM resulted in decreased expression of
PDGF-B compared with the exposure of same cells to
CACM. However, exposure of neurons to CM from all the
treatments failed to decrease PDGF-B mRNA (Figures 3b, d
and f), thereby suggesting a posttranscriptional regulatory
mechanism.
Exosomes released from astrocytes treated with mor-
phine and Tat contain miR-29b that can be taken up by
neurons. Exosomes are extracellular vesicles derived from
cells that function as ‘bioactive vesicles’ to promote cell–cell
communication and immunoregulation.20 They have been
isolated from bronchoalveolar lavage, CSF, urine, serum,
bile and breast milk. Exosomes can shuttle various mole-
cules, including miRNAs that can be transported to the











































































Figure 1 SIV and morphine alter miRNA profiling in basal ganglia of macaques. (a) Unbiased heat map correlating the expression of various miRNAs in the basal ganglia
of SIV-infected macaques with and without morphine dependence, with colors indicating relative expression levels. (b) Real-time PCR demonstrating increased miR-29b
expression in basal ganglia of SIV-infected and morphine-dependent macaques. (c) In situ hybridization demonstrating increased miR-29b expression in neurons adjacent to
astrocytes (arrows) in the basal ganglia of morphine-dependent SIV-infected macaques. Scale bar¼ 10mm
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number of exosomes as well as their miRNA content has
been found to be elevated in various diseased states in
humans.21 For example, it has been reported that during
inflammation, glial cells can release transmit signals and
soluble mediators through exosomes, which, in turn, have
critical roles in vascular and neuronal regeneration.22,23
On the basis of these findings, we hypothesized that SIV/SIV
protein Tat and/or morphine could alter the expression of
astrocyte-released miR-29b, which, in turn, could be deliv-
ered via the exosomes to the neighboring neurons, resulting
in targeted downregulation of the neurotrophic factor PDGF-
B. In our efforts to test this hypothesis, we first monitored the
release of exosomes in CM of astrocytes. Exosomes were
readily detectable in A172 CM as assessed by electron
micrography (Figure 4a) and western blotting (Figure 4b),
using the antibody specific for exosome marker-Tsg101.
Intriguingly, elevated miR-29b expression was detected in
exosomes purified from CM of astrocytes treated with
morphine and Tat, and this effect was inhibited by pre-
treating the cells with either the exosome inhibitor (dimethyl
amiloride, DMA) or the lipid-raft disruption drug (methyl-b-
cyclodex, MbCD), both of which are known to inhibit
exosome release (Figure 4c). Presence of miR-29 in the
released exosomes was further confirmed by virtual northern
blots (Figure 4d). In addition to miR-29b, there was also
decreased expression of other irrelevant miRs, such as miR-
221 and miR-222, in the exosomes purified from CM of
astrocytes treated with morphine and Tat (Supplementary
Figure 2). The next step was to examine the transfer of miR-
29b from the astrocytes to the neurons. For this, neurons
were cultured in the presence of exosomes released from
astrocytes transfected with fluorescently labeled reporter
miR-29. As observed in Figure 4f, neurons cultured with the
isolated exosomes for 4 h demonstrated a fine granular
fluorescent pattern within their cytoplasm, suggesting the
incorporation of the fluorescently labeled reporter FAM-miR-
29 within the neurons. Having determined the transfer of
miR-29b from the astrocyte released exosomes to the
neurons, the next step was to examine the functionality of
the transferred miR-29b in the neurons by assessing the
expression of its target gene, PDGF-B. Neuronal SH-SY5Y
cells cultured in the presence of exosomes purified from CM
obtained from either untreated or Tat- and morphine-treated
A172 cells were assessed for expression of the PDGF-B
chain protein. As shown in Figure 4e, neuronal cells cultured
with miR-29b containing exosomes purified from stimulated
A172 cells demonstrated reduced expression of the survival
PDGF-BB
β-actin




















































Figure 2 Downregulation of PDGF-BB protein in basal ganglia of SIV-infected macaques with opiate abuse. (a) Western blot analysis of PDGF-BB expression in basal
ganglia of untreated or SIV-infected macaques with and without morphine dependence. (b) Real-time PCR analysis of PDGF-B mRNA expression in basal ganglia of SIV-













































































































































































Figure 3 Conditioned media from HIV-1 Tat-and morphine-treated astrocytes
downregulated PDGF-BB expression in neurons. (a, c and e) Western blot analysis
of PDGF-BB protein expression in neurons treated with astrocyte conditioned
medium. (b, d and f) Real-time PCR analysis of PDGF-B chain expression in
neurons treated with astrocyte conditioned medium. Bars represent the
mean± S.D. from three independent experiments. NCM, nonculture medium;
CACM, control astrocyte CM; MACM, morphine-treated astrocyte CM; TACM, Tat-
treated astrocyte CM; MTACM, morphine and TACM
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G Hu et al
4
Cell Death and Disease
A172 exosomes





































































































































































Figure 4 Exosomes released from astrocytes treated with morphine and Tat contain miR-29b that can be taken up by neurons. (a) Electron micrograph of A172
exosomes. The image shows small vesicles of approximately 50–80 nm in diameter. Scale bar¼ 100 nm. (b) Western blot characterization of astrocyte exosomes. Exosome
protein released from astrocytes was separated on SDS-PAGE and electroblotted to nitrocellulose membrane. Blots were probed with exosome marker antibody against
Tsg101. (c) Rat primary astrocytes and A172 cells were pre-treated with exosome inhibitor (DMA) or lipid-raft pathway inhibitor (MbCD) for 1 h (to inhibit exosome release),
followed by morphine and Tat treatment exposure for 24 h. Total RNA from exosomes was then analyzed by real-time PCR for miR-29b. Bars represent the mean± S.D. from
three independent experiments. *Po 0.05 versus control. (d) MiR-29 was increased in morphine and Tat-treated A172 released exosomes, as assessed by virtual northern
blot. Cells were exposed to morphine and Tat for 24 h. Exosomes were isolated and followed by virtual northern blot for miR-29. Small nuclear RNA RNU6B (U6) was blotted to
ensure equal loading. (e) SH-SY5Y cells were incubated with exosomes released from control or morphine- and Tat-treated A172 cells for 24 h, followed by western blot for
PDGF-BB. (f) Detection of miR-29 transferred into SH-SY5Y cells using FAM-labeled microRNA mimic (miR-29). SH-SY5Y cells were incubated for 3 h at 371C with
exosomes isolated from A172 cells transfected with FAM-labeled miR-29 mimic (exosome FAM miR-29). The uptake of exosomes was evaluated by confocal microscopy.
MiRNAs incorporated within SH-SY5Y cells were detected as green fluorescence signal of FAM fluorophores (original magnification  400). Scale bar¼ 20mm
MiR-29b regulates PDGF-B and neuronal survival
G Hu et al
5
Cell Death and Disease
gene – PDGF-B. This result was further confirmed by detection
of miR-29b in SH-SY5Y cells using FAM-labeled microRNA
mimics (miR-29), as shown in Figure 4f. Taken together, these
findings implicate that Tat- and morphine-stimulated astrocytes
release exosomes containing miR-29b, which can be taken up
by neighboring neurons, resulting in downregulation of the
expression of the target gene – PDGF-B.
MiR-29b targets PDGF-B 30-UTR resulting in transla-
tional suppression. Having determined the uptake of
exosomes containing miR-29b by SH-SY5Y cells, it was
subsequently important to determine whether the transferred
miR-29b, once inside the cells, could bind directly to the
30-untranslated region (30-UTR) of the target mRNA and
inhibit its translation. SH-SY5Y cells were therefore trans-
fected with a PDGF-B Luc reporter construct, wherein Luc
expression was regulated by the PDGF-B 30-UTR, an miR-
29b potential binding element (Figure 5a). Cotransfection of
SH-SY5Y cells with both miR-29b with PDGF-B-Luc con-
structs resulted in a significant decrease in Luc activity,
suggesting thereby the preferential binding of miR-29b with
the 30-UTR of PDGF-B. As a negative control, neuronal cells
were also cotransfected with a construct containing muta-
tions in the miR-29-binding region of the 30-UTR–PDGF-B.
As expected, transfection of cells with the PDGF-B 30-UTR
Mut did not downregulate Luc activity (Figure 5b). Recipro-
cally, these findings were further validated by knocking down
the expression of endogenous miR-29b by cotransfecting
cells with anti-miR-29b. As expected, cotransfection with
anti-miR-29b resulted in significant enhancement of Luc
activity (Figure 5b). Further confirmation of the role of miR-
29b in regulating the PDGF-B chain translation was carried
out by overexpressing miR-29b in the neuronal SH-SY5Y
cells, which were transfected with the precursor miR-29b and
subsequently examined for the expression of PDGF-B
protein. As shown in Figure 5c, cells transfected with the
precursor miR-29b demonstrated reduced expression of
PDGF-B protein compared with cells transfected with an
unrelated precursor miRNA control. Reciprocally, and in
contrast, transfection of anti-miR-29b (to knock down
endogenous miR-29b) resulted in enhanced expression of
target protein. These results thus underpin the role of miR-
29b in regulating PDGF-B protein expression via a post-
transcriptional mechanism.
MiR-29b shuttled through exosomes released from
stimulated astrocytes regulates neuronal survival. To
determine whether miR-29b transferred from the exosomes
released in the CM of astrocytes stimulated with Tat- and
morphine-controlled neuronal survival by regulating the
survival factor PDGF-B, both rat primary neurons as well
as SH-SY5Y cells (undifferentiated and differentiated) were
treated with the respective CM (untreated and treated with
Tat and morphine) and monitored for cell viability. As shown
in Figure 6a, exposure of both primary as well as neuronal
cell line with MTACM resulted in decreased cell viability
compared with the cells treated with CACM. These findings
were also confirmed using MAP-2 staining on cultured rat
primary neurons. As shown in Figure 6b, MTACM exposure
of neurons resulted in increased neuronal damage compared
with cells exposed to CACM. To investigate whether miR-29b
present in the Tat- and morphine-treated astrocyte CM
regulated cell viability, SH-SY5Y cells were transfected with
either the pre-miR-29b or anti-miR-29b for 48 h and subse-
quently assessed for cell viability using the MTT (3-(4,5-
dmethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
assay. As shown in Figure 6c, cells transfected with pre-
miR-29b demonstrated decreased cell viability, and cells
transfected with the anti-miR-29b, in contrast, exhibited
increased cell viability compared with the controls. To further
confirm the specificity of miR-29b, SH-SY5Y cells were
transfected with miR-29 precursor in the presence or
absence of PDGF-BB protein and assessed for cell viability.
As shown in Figure 6c, cells transfected with miR-29b
precursor exhibited decreased cell viability, and in contrast,
transfected cells treated with PDGF-BB demonstrated a
reversal of cell viability. To further examine whether
exosomes, the potential carriers of miR-29b, in the stimu-
lated astrocyte CM were the key factors involved in
regulating cell viability, neurons exposed to purified exo-
somes isolated from CM of either untreated or HIV-1 Tat- and
morphine-treated astrocytes were monitored 48 h later for
cell viability using the MTT assay. As shown in Figure 6d,
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Figure 5 MiR-29b targets PDGF-B 30-UTR resulting in translational suppression.
(a) PDGF-B mRNA shows one potential binding site in the 30-UTR for miR-29.
(b) Binding of miR-29b to the potential binding site in the PDGF-B 30-UTR resulted in
translational suppression. SH-SY5Y cells were cotransfected with the reporter
construct and miR-29b precursors anti-miR-29b for 24 h. Luc activity was then
measured and normalized to the control b-gal levels. (c) SH-SY5Y cells were
transfected with either miR-29b precursor or anti-miR-29b for 24 h followed by western
blotting for PDGF-BB. Bars represent the mean± S.D. from three independent
experiments. *Po 0.05 versus control; #Po 0.05 versus treated control
MiR-29b regulates PDGF-B and neuronal survival
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stimulated astrocytes exhibited decreased viability likely via
downregulation of PDGF-B expression in these cells.
Discussion
Despite the advent of anti-retroviral therapy, prevalence of
HIV-1-associated complications is on the rise, affecting
almost 60% of the infected individuals and thereby impairing
their quality of life. Use of illicit drugs, a commonly observed
feature among HIV-infected individuals, further compounds
this problem. Combined HIV-1 infection and opiate depen-
dence is becoming an emerging problem in the post-HAART
era, as infected people continue to live longer. In fact, it is
estimated that drug abuse may be the leading cause of HIV
transmission in the United States. Brain tissues express a
high number/density of m-opioid receptors, making the CNS
uniquely susceptible to the combined effects of opiate
substance abuse and HIV-1 infection. The interplay of the
two thus raises concerns regarding their effects on disease
severity and rate of progression.24
Given the difficulties of studies on drug abusers, controlled
studies on the effects of drugs are best done in animal models.
Several studies have utilized the SIV/AIDSmacaque model to
better understand the influence of opiate dependency on HIV
progression to AIDS. SIV infection in rhesus macaques is one
of the best models of HIV-1 infection in humans, as the virus
has a CCR5 phenotype similar to that of HIV.4 Although SIV
infection in macaques has proved to be an excellent model of
HIV encephalitis, studies on the impact of morphine on SIVE,
as to whether it protects or mediates increased pathogenesis,
have been controversial in the field.6,24More recently, findings
from our lab have demonstrated thatmorphine-dependence in
SIV-infected macaques resulted in increased mortality in a
subset of animals, and this was accompanied by exacerbated
neuropathology.5 We thus hypothesized that some of the
adverse effects of opiates on HIV/SIV-infected CNS could be
modulated by miRNA-mediated downmodulation of neuro-
protective factors. We performed miRNA arrays on the RNA
isolated from archival brain tissue (basal ganglia region –
critical for HIV predilection) of uninfected and SIV-infected
macaques with and without morphine dependence. Although
significant numbers of miRNAs were differentially regulated
by SIV and morphine, we focused our studies on miRNA-29b,
which has potential binding sites on the PDGF-B 30-UTR.
In the present study, we identified miR-29b targeting the 30-
UTR region of the neurotropic gene PDGF-B chain as a highly
expressed miRNA in the basal ganglia region of SIV-infected,
morphine-dependent macaques. To validate these findings in
cell culture, we first treated neuronal cell line SH-SY5Y and rat
primary neurons with morphine and HIV Tat to mimic the
in vivo scenario. Intriguingly, treatment of neuronswith the two
agents did not result in upregulation of miR-29b. A possible
explanation could be that neurons need signal from the
astrocytes to respond effectively. Astrocytes have been
shown to communicate to neighboring cells via gap junctions.
For example, Eugenin et al.25 have elegantly demonstrated
the role of astrocyte gap junctions in mediating blood–brain
barrier damage, possibly by triggering bystander cellular
dysfunction and endothelial apoptosis. In the present study,
we demonstrate another mechanism of cellular communica-
tion involving indirect intercellular transfer of miRNAs by
exosomes during neuronal degeneration.








































































































































































































Figure 6 MiR-29b is involved in neuronal death induced by morphine and Tat astrocyte conditioned media. (a) Cell viability of rat primary neurons and SH-SY5Y cells
(± retinoic acid) treated with the indicated conditioned media using the MTT assay after 48 h. (b) MAP-2 staining in rat primary neurons treated with indicated conditioned
media. Scale bar¼ 10mm. (c) Cell viability of SH-SY5Y cells transfected with miR-29b precursors with or without PDGF-B protein (100 ng/ml) or anti-miRs for 48 h using MTT
assay. (d) Cell viability of SH-SY5Y cells treated with indicated exosomes for 48 h followed using MTT assay. Data are mean± S.D. of three independent experiments
performed in triplicate. *Po 0.05 versus control group; #Po 0.05 versus treated control
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Neurons were treated with CM from astrocytes exposed to
morphine and Tat, followed by the assessment for the
expression of miR-29b. Our findings demonstrated that there
was increased expression of miR-29b in exosomes released
from astrocytes treated with morphine and Tat, and these
exosomes could be taken up by the neurons, leading to
neuronal death. A recent study demonstrated an increase in a
different miRNA, miR-21, in SIV and HIV encephalitis in the
absence of drugs of abuse.13 Although expression was found
in neurons in the infected brains, it is not known whether
miR-21 can be induced in neurons or, similar to the current
findings, in exosomes, or whether othermechanisms can lead
to their transfer to neurons
There is ample evidence in literature that many cells either
constitutively or following stimulation release vesicles or
microparticles that can function as vehicles for intercellular
communication. Basically, two modes of microvesicle release
have been characterized: exocytosis of multivesicular bodies
(MVBs) and the direct budding from the plasma membrane
small vesicles. Meldolesi and colleagues26 coined the term
‘exosomes’ for the MVB-derived microvesicles, whereas
vesicles directly budding from the plasma membrane are
referred to as ‘shedding vesicles’. Previous studies have
reported that exosomes express certain specific marker
proteins such as ALix, Tsg101 and CD9.22 In the brain, one
of the functions of astrocytes is their bidirectional commu-
nication with other cells specifically neurons. Interestingly,
Guescini et al.22 have reported that astrocytes release
exosomes carrying protein and mitochondrial DNA, which
can be transferred between cells. Our in vitro data demon-
strates that following exposure of astrocytes to HIV Tat and
morphine, there is increased expression of miR-29b that is
released via the exosomes and can be taken up by the
neurons, resulting in concomitant decrease in PDGF-B
expression in the latter cells. These studies highlight the
significance of communication between astrocyte and neuron
through exosome modulating miRNAs and their target gene
PDGF-B in neurons.
It is intriguing to speculate that such a cell-to-cell commu-
nication could have advantages for transmission of signals
from one cell to the other. As one of the functions of astrocytes
is to maintain neuronal homeostasis, the exosomes/micro-
vesicles mode of shuttling mRNAs and miRNAs could be an
additional mechanism by the cells for regulating the genetic
makeup of the recipient cells. Furthermore, the release of
exosomes/microvesicles could be a means to allow a cell to
communicate to another cell that is physically apart. Exo-
somes have been identified in body fluids such as cerebrosp-
inal fluid, urine, amniotic fluid, malignant ascites,
bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva
and blood, which indicate organs might exchange information
via exosomes.27
MiR-29a and b are highly expressed in the CNS. According
to deep-sequencing studies by different groups, miR-29 is one
of the most abundant miRNAs in the adult hippocampus and
cortex.28–30 In rodents, the expression of miR-29 increases
with neuronal development and reaches highest levels in
adulthood.31 Moreover, miR-29 contributes to increased
BACE1 and ab levels in sporadic Alzheimer’s disease.31
Although there is increased expression of miR-29b in the
CNS, its expression in the basal ganglia is lower compared
with other brain regions (Supplementary Figure 3). Further-
more, reports that miR-29 is more strongly expressed in
astrocytes than in neurons32 lends credence to our findings
that miR-29b is shuttled via exosomes from stimulated
astrocytes to neurons. Although our findings readily suggest
that shuttling of exosomal miR-29 from astrocyte affects
neuronal viability by targeting PDGF-B expression, we cannot
directly evaluate the stoichiometric relationship between the
amount of exosomal miR-29 and PDGF-B expression in vivo.
In keepingwith the findings on the role of dysregulatedmiR-29
in cardiac fibrosis, we also observed that even a minimal
decrease in miRNA expression was accompanied by a robust
increase in its target gene expression.33 Intriguingly, in our
studies we demonstrate that inhibiting miR-29b expression in
neurons resulted in enhanced neuronal survival in vitro,
whereas overexpressing miR-29b mimic suppressed neuro-
nal viability. Tat and morphine could thus modulate the
expression of miR-29b, resulting in downregulation of the
neurotrophic factor PDGF-B in neurons. This is the first report
to demonstrate that exosomes released from astrocytes can
shuttle themiRNAs to neurons, thereby functionally regulating
gene expression in neurons.
In addition to regulating the neurotropic factors, studies
have also indicated that miR-29b can also function as an
inhibitor of tumor growth and a stimulator of cell differentia-
tion.34,35 Furthermore, Nathans et al.36 also identified that
miR-29a can specifically target HIV-1 mRNA and represses
viral replication by accumulating viral mRNA in P-bodies in
human T lymphocytes. Our studies have revealed that PDGF-B
is an important target for miR-29b in neurons. Upregulated
expression of miR-29b in HIV/SIV and drug abusers, through
repression of PDGF-B, and potentially other target genes such
as MCP-1, could lead to deficits in neurocognitive functions as
seen in HIV-infected drug abusers.
In conclusion, our data suggest that the exosomes released
from astrocytes exerted neurotoxic effects on neurons. The
mechanism of this effect is, at least in part, related to the
increased miR-29b, which was taken up by neurons, leading
to decreased PDGF-B expression. Regulation of miR-29b
expression in exosomes released from astrocytes might be a
putative therapeutic strategy against the pathogenesis of HIV-
associated neurological disorder.
Materials and Methods
Macaques and viruses. Sixteen, 2- to 3-year-old, Indian strain rhesus
macaques (Macaca mulatta) were purchased from the Caribbean Research
Primate Center and individually housed in steel-holding cages in two dedicated
rooms within the AAALAC-approved animal facility at the University of Kansas
Medical Center. The monkeys were exposed to 12-h light–dark cycles daily and
given laboratory chow and water ad libitum along with daily snacks. All cages were
equipped with environmental enrichments. The animals were tested for
tuberculosis, herpes B virus and simian retrovirus, and were found to be negative
in all these tests. All animal protocols were approved by the local animal care
committee in accordance with the Guide for the Care and Use of Laboratory
Animals. The animals were randomly divided into two groups: SIV only (V, n¼ 4)
and morphineþ SIV (MþV, n¼ 12). Morphine was administered intramuscularly
(IM) to Mþ V macaques 4 times daily at 6-h intervals, at a dose of 3 mg/kg with a
1-ml syringe (27.5 G needle). The macaques were gradually acclimated to
morphine by starting with 1mg/kg for 1 week and escalating to a final dose of
3 mg/kg in 1mg/kg increments per week. The V-group animals were injected with
saline IM at the same time intervals. Morphine administration was maintained
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throughout the study to avoid withdrawal effects. For all animal studies, clinical-
grade morphine was purchased from the University of Kansas Pharmacy and was
used at a final dose of 3 mg/kg.5
Reagents. Morphine was purchased from R&D Systems (Minneapolis, MN,
USA) and Tat1-72 was obtained from the University of Kentucky. Chemical
inhibitors, including MbCD and DMA were purchased from Sigma (St. Louis, MO,
USA). PDGF-B antibody was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Tsg101 and b-actin antibodies were purchased from Abcam
(Cambridge, MA, USA) and Sigma, respectively.
Isolation of rat primary neurons and astrocytes. Primary cultures of
rat neurons and astrocytes were prepared as described previously, with slight
modifications.37 Briefly, cortex tissues were dissected from embryonic day 18–19
Sprague-Dawley rats and dissociated with mild mechanical trituration. Dissociated
cells were seeded firstly at 5–105 cells/well on 24-well culture plates, and
maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F-12 supplemented
with 10% fetal bovine serum and 1% antibiotic. After 1 day, the cultures were
supplemented with serum-free neurobasal medium containing B27 (50 : 1), 2mM
glutamax and 1% antibiotic. Seven days following the initial plating, cultures
consisted of 98% neuron-specific nuclear protein-immunoreactive (IR) neurons.
Rat primary astrocytes were prepared from whole brains of postnatal (1- to 2-day-
old) Sprague-Dawley rats and plated on poly-D-lysine pre-coated cell culture flasks
containing DMEM (10% fetal calf serum, 100 U/ml penicillin and 100mg/ml
streptomycin). The cells were grown in a humidified atmosphere of 5% CO2/95% air
at 371C. When the astrocytes reached confluence, they were passaged by
trypsinization and plated at a density of 106 cells/well on 24-well culture plates in a
final volume of 1 ml of DMEM and grown in a humidified atmosphere of 5% CO2/
95% air at 371C. Two days later, the astrocytes were used for experimentation.
Immunocytochemical analyses demonstrated that the cultures comprised of 4 95%
glial fibrillary acid protein-positive astrocytes.
Cell culture and treatments. Neuroblastoma SH-SY5Y cells were plated at a
density of 1 105 per ml and cultured in a 1 : 1 mixture of Eagle’s minimum essential
medium containing nonessential amino acids (Gibco, Gaithersburg, MD, USA) and
F12 medium (Gibco) supplemented with heat-inactivated fetal bovine serum (10% v/v)
and 2mM glutamine at 371C in 5% CO2. For some experiments, confluent cells were
replated at 1–5 105 cells/ml and differentiated by treatment with 10mM retinoic acid
(Sigma) for 7 days with medium changes every 2 days. For the experiments with
differentiated cells, the cells were serum-starved for 24 h in the presence of 10mM
retinoic acid (Sigma). Human astrocytoma cell line A172 (ATCC CRL-1620) were
grown in DMEM supplemented with 10% fetal calf serum plus antibiotics.
Western blots. Whole-cell lysates were obtained from cells or tissues with the
Mammalian Cell Lysis kit (Sigma). Equal amounts of the proteins were
electrophoresed in a SDS-polyacrylamide gel (12%) under reducing conditions,
followed by transfer to PVDF membranes. The blots were blocked with 5% nonfat dry
milk in TBST. Western blots were then probed with antibodies recognizing the PDGF-
B (1 : 1000, Santa Cruz Biotechnology), Tsg101 (1 : 1000, Abcam) and b-actin
(1 : 5000, Sigma). The secondary antibodies were alkaline phosphatase conjugated
to goat anti-mouse/rabbit IgG (1 : 5000) as described previously.37 Densitometric
levels of PDGF-B signals were quantified and expressed as their ratio to b-actin.
MiRNA microarray studies. Total cellular RNA was isolated from frozen
( 801C) brain specimens by using TRIzol (Invitrogen, Carlsbad, CA, USA) for
the monkey samples, followed by column purification (miRNeasy; Qiagen,
Valencia, CA, USA) as per the manufacturer’s instructions. Affymetrix microarray
was performed by Asuragen, Inc. (Austin, TX, USA).
Real-time PCR. For quantitative analysis of mRNA expression, comparative
real-time PCR was performed with the use of the SYBR Green PCR Master Mix
(Applied Biosystems, Carlsbad, CA, USA). The sequences for the amplification of
human PDGF-B were: 50-TGTGGGCAGGGTTATTTAATATGG-30 (forward) and
50-CCATTGGCCGTCCGAATC-30 (reverse). The primer sequences for the
amplification of GAPDH were as follows: 50-GCCAAAAGGGTCATCATCTC-30
(forward); 50-GGCATGGACTGTGGTCATGAG-30 (reverse).
For analysis of miR-29b, total RNA was isolated from cells as described above.
Comparative real-time PCR was performed by using the Taqman Universal PCR
Master Mix (Applied Biosystems). Specific primers and probes for mature miR-29b
and snRNA RNU6B were obtained from Applied Biosystems. All reactions were run
in triplicate. The amount of miR-29b was obtained by normalizing to snRNA RNU6B
and relative to control as previously reported.38
Virtual northern blots. MiR-29 and snRNA U6 real-time PCR products were
run on a 15% Tris/Borate/EDTA (90 mM Tris/64.6 mM boric acid/2.5 mM EDTA
(pH8.3)) urea gel (Invitrogen) and transferred to a Nytran nylon transfer membrane
(Ambion, Austin, TX, USA). An LNA DIG-probe for miRNA-29b (Exiqon, Vedbaek,
Denmark) was hybridized using UltraHyb reagents (Ambion) according to the
manufacturer’s instructions, with blotted snRNA RNU6B as a control.
MiRNA in situ hybridization. In situ hybridization for miRNA was
performed as described previously. Following deparaffinization and antigen
retrieval with citrate, sections were pre-hybridized in hybridization buffer (50%
formamide, 10mM Tris-HCl, pH 8.0, 200mg/ml yeast tRNA, 1 Denhardt’s
solution, 600mM NaCl, 0.25% SDS, 1mM EDTA, 10% dextran sulfate) for 1 h at
37 1C in a humidified chamber. LNA-modified miR-29b, labeled at both the 50- and
30-ends with digoxigenin (Exiqon), were diluted to a final concentration of 2 pM in
hybridization buffer, heated to 651C for 5 min and separately hybridized to the
sections at 371C overnight. The slides were then washed twice in hybridization
buffer (without probe) at 37 1C, followed by washing three times in 2 SSC and
twice in 0.2 SSC at 421C. They were then blocked with 1% BSA and 3%
normal goat serum in 1 PBS for 1 h at room temperature, and incubated with
anti-digoxigenin conjugated with horseradish peroxidase (1 : 100, Roche
Diagnostics GmbH, Mannheim, Germany) and anti-MAP2 (1 : 1500, Sternberger
Monoclonals Inc., Baltimore, MD, USA) antibodies overnight at 41C. The slides
were washed twice with PBS and incubated with Alexa Fluor 568 goat anti-mouse
IgG (1 : 400, Invitrogen) antibody for 1 h at room temperature. This was followed
by two PBS washes and signal amplification (for the in situ, now labeled with
horseradish peroxidae) using TSA Cy5 kit (Perkin Elmer, Waltham, MA, USA)
according to the manufacturer’s protocol. The slides were mounted in Prolong gold
anti-fade reagent with DAPI (Invitrogen).
Transient transfection assays. Transfections of miRNAs to A172 cells
were performed using the Lipofectamine 2000 Transfection Reagent (Invitrogen)
according to the manufacturer’s protocol. FAM-conjugated MISSIONH microRNA
Mimics (Sigma; miR-29 20 nM) were used in each experiment.
Exosome purification. Exosomes were prepared from the supernatant of rat
primary astrocytes and A172 cells by differential centrifugations as previously
described,20 with some modifications. Briefly, cells were harvested, centrifuged at
1000 r.p.m. for 10min to eliminate cells, and again spun at 10 000 r.p.m. for 30min,
followed by filtration through 0.22mm filter to remove cell debris. Exosomes were
pelleted by ultracentrifugation (Beckman Ti70 rotor, Brea, CA, USA) at 44 000 r.p.m.
for 70min. Exosomes were assessed for their protein content using BCA Protein
Assay Kit (Pierce, Rockford, IL, USA). For real-time PCR, the RNA from the cell pellets
was extracted by Trizol. Tsg101 was detected by western blot as an exosome marker.
Electron microscopy. Exosome pellets were prepared for negative staining
and immunogold double-labeling employing a slightly modified procedure. Using
wide-bore tips, 3ml of exosome pellet was gently placed on 200-mesh formvar-
coated copper grids, allowed to adsorb for 4–5min, and processed for standard
uranyl acetate staining. In the last step, the grid was washed with three changes of
PBS and allowed to semi-dry at room temperature before observation in TEM
(Hitachi H7500 TEM, Tokyo, Japan).
Luciferase activity assays. Complementary 37 bp DNA oligonucleotides
containing the putative miR-29 target site within the 30-UTR of human PDGF-B
were synthesized and cloned into the multiple cloning sites of the pMIR-REPORT
Luc vector (Ambion) as previously reported.11 In this vector, the posttranscriptional
regulation of Luc was potentially regulated by miRNA interactions with the PDGF-
B 30-UTR. Another pMIR-REPORT Luc construct containing mutant 30-UTR
(50-TGGTGCT-30 to 50-ACCACGA-30) was applied as a control. SH-SY5Y cells
were transfected with each reporter construct, as well as anti-miR-29b or miR-29b
precursor, followed by assessment of Luc activity 24 h after transfection. Luc
activity was measured and normalized to control b-gal.
Immunohistochemistry. Immunohistochemical analysis of PDGF-B was
carried out on archival paraffin-fixed tissue sections of brain from uninfected or
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SIV-infected macaques with or without morphine dependence, as described earlier.5
Sections from basal ganglia region of macaques were treated with rabbit polyclonal
PDGF-B antibody (Santa Cruz Biotechnology), followed by treatment with Alexa
Fluor 594-conjugated anti-rabbit secondary antibody (1 : 500; Invitrogen) for 30min
at room temperature and mounted in Slow Fade anti-fade reagent with 4,6-
diamidino-2-phenylindole (Molecular Probes, Eugene, OR, USA). Images were
captured using inverted fluorescence microscope TE2000-E (Nikon, Tokyo, Japan).
MTT assay. Cell viability was measured by the MTT method. Briefly, cells were
collected and seeded in 96-well plates. Different seeding densities were optimized
at the beginning of the experiments. Cells were exposed to nonculture medium or
astrocyte-CM. After incubation for up to 48 h, 20ml MTT tetrazolium salt dissolved
in Hank’s balanced salt solution at a final concentration of 5mg/ml was added to
each well and incubated in CO2 incubator for 1–4 h. Finally, the medium was
aspirated from each well and 200ml of dimethyl sulfoxide was added to dissolve
the formazan crystals, and the absorbance of each well was obtained using a plate
counter at test and reference wavelengths of 570 and 630 nm, respectively. All
experiments were repeated at least three times.
Statistical analysis. Statistical analysis was performed using one-way
analysis of variance with a post hoc Student’s t-test. Results were judged
statistically significant if Po 0.05 by analysis of variance.
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